Anti-interleukin-6

Mm-hmm.

So we're going upstream from IL-1 beta, and then there are the anti-IL-6 studies which are underway.

We'll hear about Zeus probably in 2026, which is the first large-scale trial with an anti-IL-6 agent, and so it's an exciting time.

We have colchicine, which we have in hand, um, and Italians have been very much in the, in the forefront of using colchicine for cardiovascular, uh, indications with Imazio.

Uh, so you were pioneers in that in your country.

This was non-inferior to aflibercept for wet AMD.

They also talked about an anti-IL-6 and a VEGF bispecific.

Um, what's your read on that one? Is this, is, is that sort of like phase two for Kodiak?

Well, you know, the, the rationale behind IL-6 and wet macular degeneration is not as strong as for uveitic macular edema.

Mm-hmm.

It wouldn't surprise me at all if the FDA ruled favorably for this as a, as a treatment, and it could help our patients that have adverse responses to steroids a- and whatnot.

Is there gonna be a big educational push on the value of anti-IL-6 as a mechanism, or is this just gonna be the kinda thing where if it works, it works, and the mechanism is not really of interest?

No, I think it's already starting.